|Articles|July 1, 1998

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
Volume 4
Issue 7 Suppl

New Drug Class Offers Benefits in Heart Failure

Author(s)Edward P. Havranek, MD

Download PDF: New Drug Class Offers Benefits in Heart Failure

Articles in this issue

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

over 27 years ago

Article

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

over 27 years ago

Article

Gene Polymorphism Influences Response to Angiotensin Blockade

over 27 years ago

Article

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

over 27 years ago

Article

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

over 27 years ago

Article

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

over 27 years ago

Article

What are the Pharmacological Differences Between Angiotensin II Antagonists

over 27 years ago

Article

Clinical Implications of Differences Between Angiotensin II Antagonists

over 27 years ago

Article

Exploring the Benefits Beyond Blood Pressure Control

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

New Drug Class Offers Benefits in Heart Failure

Articles in this issue

Newsletter

Related Content

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps

Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns

5 Ongoing Phase 3 Trials in Hematologic Malignancies

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

Novel CLL Therapies Prompt New Treatment Considerations